Skip to main content

Practical Management of Psoriasis in the Elderly

Epidemiology, Clinical Aspects, Quality of Life, Patient Education and Treatment Options

Drugs & Aging volume 19, pages 847–863 (2002)Cite this article

Abstract

Psoriasis in the elderly will constitute a significant challenge for the practising physician in this new millennium. Special considerations for the elderly include drug-induced or drug-aggravated psoriasis, especially for patients receiving polypharmacy or with recent worsening or poor response to conventional therapy. Other frequently encountered forms of psoriasis in the elderly include psoriatic arthritis and its complications, inverse psoriasis and potentially life-threatening complications such as erythrodermic or acute pustular psoriasis, where early recognition and systemic therapy is critical.

Faced with an array of topical and systemic drug therapy options, it is of paramount importance that the physician remains focused on the holistic management of the patient, in order to achieve optimal compliance and benefit. This can be achieved through careful attention to quality-of-life issues, especially since many elderly patients may have other medical, social and economic comorbidities that can further negatively affect their overall quality of life. It is also essential that the severity of psoriasis be assessed on a more balanced, holistic scale that incorporates both physical and psychological parameters, such as the Salford Psoriasis Index.

The patient and caregiver education should be multi-faceted, regularly conducted and practically orientated. Treatment goals should be kept simple and individualised for each patient, based on concomitant comorbidities, potential adverse effects, existing quality of life, self-care capability, drug history, caregiver situation, financial needs, feasibility for follow-up and patient’s preferences.

Topically applied medications, such as topical corticosteroids, salicylic acid, tar and dithranol preparations, calcipotriol and tazarotene, are the favoured first-line therapeutic options in the elderly. Narrowband ultraviolet B phototherapy is also well established as a standard therapy for psoriasis. Systemic therapy with agents such as methotrexate, acitretin and cyclosporin should be judiciously reserved for severe, extensive cases in view of their lower therapeutic index in the elderly. The ambulatory psoriasis treatment centre is an integral part of the overall cost-effective management of patients with psoriasis that can function as a ‘one-stop’ treatment and resource centre for the elderly patient.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Fig. 1

References

  1. US Census Bureau [online]. Available from URL: www.census.gov [Accessed 2002 Oct 15]

  2. Anderson GF, Poullier JP. Health spending, access, and outcomes: trends in industralized countries. Health Aff 1999; 18: 178–92

    CAS  Google Scholar 

  3. Smith ES, Fleischer Jr AB, Feldman SR. Demographics of aging and skin disease. Clin Geriatr Med 2001; 17(4): 631–41

    PubMed  CAS  Google Scholar 

  4. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485–96

    PubMed  CAS  Google Scholar 

  5. Bell LM, Sedlack R, Beard CM, et al. Incidence of psoriasis in Rochester, Minnesota, 1980–1983. Arch Dermatol 1991; 127: 1184–7

    PubMed  CAS  Google Scholar 

  6. Swanbeck G, Inerot A, Martinsson T, et al. A population genetic study of psoriasis. Br J Dermatol 1994; 131: 32–9

    PubMed  CAS  Google Scholar 

  7. McFadden N, Hande K-O. A survey of elderly new patients at a dermatology outpatient clinic. Acta Derm Venereol (Stockh) 1989; 69: 260–2

    CAS  Google Scholar 

  8. Yap KB, Siew MG, Goh CL. Pattern of skin diseases in the elderly seen at the National Skin Centre (Singapore) in 1990. Singapore Med J 1994; 35: 147–50

    PubMed  CAS  Google Scholar 

  9. Liao YH, Chen KH, Tseng MP, et al. Pattern of skin diseases in a geriatric patient group in Taiwan: a 7-year survey from the outpatient clinic of a University Medical Centre. Dermatology 2001; 203: 308–13

    PubMed  CAS  Google Scholar 

  10. Gligora M, Arzensek J, Rems D, et al. Psoriasis in the third age. Acta Derm Venereol (Stockh) 1989; 146: 168–70

    CAS  Google Scholar 

  11. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450–6

    PubMed  CAS  Google Scholar 

  12. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol (Stockh) 1981; 61: 344–6

    CAS  Google Scholar 

  13. Buntin DM, Skinner Jr RB, Rosenberg EW. Onset of psoriasis at age 108. J Am Acad Dermatol 1983; 9: 276–7

    PubMed  CAS  Google Scholar 

  14. Zelickson BD, Muller SA. Generalized pustular psoriasis: a review of 63 cases. Arch Dermatol 1991; 127: 1139–45

    Google Scholar 

  15. Tay YK, Tham SN. The profile and outcome of pustular psoriasis in Singapore: a report of 28 cases. Int J Dermatol 1997; 36: 266–71

    PubMed  CAS  Google Scholar 

  16. Wright V, Roberts MC, Hill AGS. Dermatological manifestations in psoriatic arthritis. Acta Derm Venereol 1979; 59: 235–40

    PubMed  CAS  Google Scholar 

  17. Scarpa R, Oriente P, Pucina A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984; 23: 246–50

    PubMed  CAS  Google Scholar 

  18. Camp RDR. Psoriasis. In: Champion RH, Burton JL, Burns DA, et al., editors. Textbook of Dermatology. 6th ed. Oxford: Blackwell Science, 1998: 1589–1649

    Google Scholar 

  19. Fischer M, Gemende I, Marsch WC, et al. Skin function and skin disorders in Parkinson’s disease. J Neural Transm 2001; 108(2): 205–13

    PubMed  CAS  Google Scholar 

  20. Fleischer AB, Feldman SR, Rapp SR, et al. Alternative therapies are commonly used within a population of psoriasis patients. Cutis 1996; 11: 216–20

    Google Scholar 

  21. Katugampola G, Katagampola S. Chloroquine and psoriasis. Int J Dermatol 1990; 29: 153–4

    PubMed  CAS  Google Scholar 

  22. Slagel GA, James WD. Plaquenil induced erythroderma. J Am Acad Dermatol 1985; 12: 857–62

    PubMed  CAS  Google Scholar 

  23. Abel EA, Dicicco LM, Orenberg EK, et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15: 1007–22

    PubMed  CAS  Google Scholar 

  24. Heng MCY, Heng MK. Beta-adrenoceptor antagonist-induced psoriasiform eruption: clinical and pathogenetic aspects. Int J Dermatol 1988; 27: 619–27

    PubMed  CAS  Google Scholar 

  25. Gold MH, Holy AK, Roenigk HH. Beta-blocking drugs and psoriasis: a review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol 1988; 19: 837–41

    PubMed  CAS  Google Scholar 

  26. Skott A, Mobacken H, Starmark JE. Exacerbation of psoriasis during lithium treatment. Br J Dermatol 1977; 96: 445–8

    PubMed  CAS  Google Scholar 

  27. Lowe NJ, Ridgway HB. Generalized pustular psoriasis precipitated by lithium. Arch Dermatol 1978; 114: 1788–9

    PubMed  CAS  Google Scholar 

  28. Sendagorta E, Allegue F, Rocamora A, et al. Generalized pustular psoriasis precipitated by diclofenac and indomethacin. Dermatologica 1987; 175: 300–1

    PubMed  CAS  Google Scholar 

  29. Ben-Chetrit E, Rubinow O. Exacerbation of psoriasis by ibuprofen [letter]. Cutis 1986; 38: 45

    PubMed  CAS  Google Scholar 

  30. Katayama H, Kawada A. Exacerbation of psoriasis induced by indomethacin. J Dermatol 1981; 8: 323–7

    PubMed  CAS  Google Scholar 

  31. Powles AV, Griffiths CEM, Seifert MH, et al. Exacerbation of psoriasis induced by indomethacin. Br J Dermatol 1987; 117: 799–800

    PubMed  CAS  Google Scholar 

  32. Meyerhoff JO. Exacerbation of psoriasis with meclofenamate [letter]. N Engl J Med 1983; 309: 496

    PubMed  CAS  Google Scholar 

  33. Barth JH, Baker H. Generalized pustular psoriasis precipitated by trazodone in the treatment of depression. Br J Dermatol 1986; 115: 629–30

    PubMed  CAS  Google Scholar 

  34. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet 1986; I: 1466–8

    Google Scholar 

  35. Harrison PV, Stones RN. Severe exacerbation of psoriasis due to terfenadine. Clin Exp Dermatol 1988; 13: 275

    PubMed  CAS  Google Scholar 

  36. Wolf R, Tamir A, Brenner S. Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica 1990; 181: 51–3

    PubMed  CAS  Google Scholar 

  37. Wolf R, Dorfman B, Krakowski A. Psoriasiform eruption induced by captopril and chlorthalidone. Cutis 1987; 40: 162–4

    PubMed  CAS  Google Scholar 

  38. Fisher DA, Elias PM, LeBoit PL. Exacerbation of psoriasis by the hypolipidemic agent, gemfibrozil. Arch Dermatol 1988; 124: 854–5

    PubMed  CAS  Google Scholar 

  39. Bergner T, Przybilla B. Psoriasis and tetracyclines. J Am Acad Dermatol 1990; 23: 770–1

    PubMed  CAS  Google Scholar 

  40. Katz M, Seidenbaum M, Weinrauch L. Penicillin-induced generalized pustular psoriasis. J Am Acad Dermatol 1987; 17: 918–20

    PubMed  CAS  Google Scholar 

  41. Fortune DG, Main CJ, O’Sullivan TM, et al. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997; 137: 755–60

    PubMed  CAS  Google Scholar 

  42. Ramsay B, O’Reagan M. A survey of social and psychological effects of psoriasis. Br J Dermatol 1988; 118: 195–201

    PubMed  CAS  Google Scholar 

  43. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401–7

    PubMed  CAS  Google Scholar 

  44. Mckenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997; 36: 388–94

    PubMed  CAS  Google Scholar 

  45. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236–44

    PubMed  CAS  Google Scholar 

  46. Ginsburg IH, Link BG. Psychological consequences of rejection and stigma feelings in psoriasis patients. Int J Dermatol 1993; 32: 587–91

    PubMed  CAS  Google Scholar 

  47. Goldsmith LA, Fisher M, Wacks J. Psychological characteristics of psoriatics. Arch Dermatol 1969; 100: 674–6

    PubMed  CAS  Google Scholar 

  48. Hardy EG, Cotterill JA. A study of depression and obsessionality in dysmorphophobic and psoriatic patients. Br J Psychiatry 1982; 140: 19–22

    PubMed  CAS  Google Scholar 

  49. Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969–73

    PubMed  CAS  Google Scholar 

  50. Feldman SR, Fleischer AB, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37: 564–9

    PubMed  CAS  Google Scholar 

  51. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patient’s beliefs and attitudes towards the disease. Br J Dermatol 1996; 135: 533–7

    PubMed  CAS  Google Scholar 

  52. Rapp SR, Cottrell CA, Leary MR. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol 2001; 145: 610–6

    PubMed  CAS  Google Scholar 

  53. Kirby B, Fortune DG, Bhushan M, et al. The Salford Psoriasis Index: an holistic measure of psoriasis. Br J Dermatol 2000; 142: 728–32

    PubMed  CAS  Google Scholar 

  54. Kirby B, Richards HL, Woo P, et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001; 45: 72–6

    PubMed  CAS  Google Scholar 

  55. Ginsburg IH. Psychological and psychophysiological aspects of psoriasis. Dermatol Clin 1995; 13: 793–804

    PubMed  CAS  Google Scholar 

  56. Lanigan SW, Farber EM. Patient’s knowledge of psoriasis. Cutis 1990; 46: 359–62

    PubMed  CAS  Google Scholar 

  57. Lanigan SW, Layton A. Level of knowledge and information sources used by patients with psoriasis. Br J Dermatol 1991; 125: 340–2

    PubMed  CAS  Google Scholar 

  58. Richards HL, Fortune DG, O’Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581–3

    PubMed  CAS  Google Scholar 

  59. van de Kerkhof PC, de Hoop D, de Korte J, et al. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000; 200: 292–8

    PubMed  Google Scholar 

  60. Noyes MA. Pharmacotherapy for elderly women. J Am Med Womens Assoc 1997; 52: 138–41

    PubMed  CAS  Google Scholar 

  61. Lebwohl M, Ali S. Treatment of psoriasis: Pt 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487–98

    PubMed  CAS  Google Scholar 

  62. Coskey RJ. Adverse effects of corticosteroids: topical and intralesional. Clin Dermatol 1986; 4: 155–60

    PubMed  CAS  Google Scholar 

  63. Weston WL, Fennessey PV, Morelli J, et al. Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas chromatographic mass spectrometry. J Invest Dermatol 1988; 90: 532–5

    PubMed  CAS  Google Scholar 

  64. May P, Stein ES, Ryler RJ, et al. Cushing syndrome from percutaneous absorption of triamcinolone cream. Arch Intern Med 1976; 136: 612–3

    PubMed  CAS  Google Scholar 

  65. Gomez EC, Frost P. Induction of glycosuria and hyperglycaemia by topical corticosteroid therapy. Arch Dermatol 1976; 112: 1559–62

    PubMed  CAS  Google Scholar 

  66. Yosipovitch G, Tan SH, Goh CL. Suggested rationale for prevention and treatment of glucocorticoid: induced bone loss in dermatologic patients. Arch Dermatol 2001; 137: 477–81

    PubMed  CAS  Google Scholar 

  67. Hehir M, du Vivier A, Eilon L, et al. Investigation of the pharmacokinetics of clobetasol propionate and clobetasone butyrate after a single application of ointment. Clin Exp Dermatol 1983; 8: 143–51

    PubMed  CAS  Google Scholar 

  68. Kligman AM. Adverse effects of topical corticosteroids. In: Christophers E, Schopf E, Kligman AM, et al., editors. Topical corticosteroid therapy: a novel approach to safer drugs. New York: Raven Press, 1988: 181–7

    Google Scholar 

  69. du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 1975; 111: 581–3

    PubMed  Google Scholar 

  70. Singh G, Singh PK. Tachyphylaxis to topical steroid measured by histamine-induced wheal suppression. Int J Dermatol 1986; 25: 324–6

    PubMed  CAS  Google Scholar 

  71. Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991; 182: 269–74

    Google Scholar 

  72. Paramsothy Y, Lawrence CM. Time course and intensity of anthralin inflammation on involved and uninvolved psoriatic skin. Br J Dermatol 1987; 116: 517–9

    PubMed  CAS  Google Scholar 

  73. Ashton RE, Andre P, Lowe NJ, et al. Anthralin: historical and current perspective. J Am Acad Dermatol 1983; 9: 173–92

    PubMed  CAS  Google Scholar 

  74. Volden G, Bjornberg A, Tegner E, et al. Short contact treatment at home with micanol. Acta Derm Venereol Suppl (Stockh) 1992; 184: 51–3

    Google Scholar 

  75. Runne U, Kunze J. Short duration therapy with dithranol for psoriasis: a new out-patient regimen. Br J Dermatol 1982; 106: 135–9

    PubMed  CAS  Google Scholar 

  76. Kowalzick L. Clinical experience with topical calcitriol in psoriasis. Br J Dermatol 2001; 144: 21–5

    PubMed  CAS  Google Scholar 

  77. Reichrath J, Muller SM, Kerber A, et al. Biologic effects of topical calcipotriol in psoriatic skin. J Am Acad Dermatol 1997; 36: 19–28

    PubMed  CAS  Google Scholar 

  78. Bruce S, Epinette WW, Funicella T, et al. Comparative study of calcipotriene ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994; 31: 755–9

    PubMed  CAS  Google Scholar 

  79. Lamba S, Lebwohl M. Combination therapy with vitamin D analogues. Br J Dermatol 2001; 144: 27–32

    PubMed  CAS  Google Scholar 

  80. Patel B, Siskin S, Krazmein BA, et al. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998; 38: 1010–1

    PubMed  CAS  Google Scholar 

  81. Speight EL, Farr PM. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol 1994; 130: 79–82

    PubMed  CAS  Google Scholar 

  82. Kragbelle K. Combination of topical calcipotriol and UVB radiation for psoriasis vulgaris. Dermatologica 1990; 181: 211–4

    Google Scholar 

  83. Molin L. Topical calcipotriol combined with phototherapy for psoriasis: the results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Dermatology 1999; 198: 357–81

    Google Scholar 

  84. Ramsay CA, Schwartz BE, Lowson D, et al. Calcipotriol cream combined with twice weekly broad band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatic combination treatment. Dermatology 2000; 200: 17–24

    PubMed  CAS  Google Scholar 

  85. Lebwohl M, Hecker D, Martinez J, et al. Interactions between calcipotriene and ultra-violet light. J Am Acad Dermatol 1997; 37: 93–5

    PubMed  CAS  Google Scholar 

  86. Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in the treatment of psoriasis vulgaris. Lancet 1991; 337: 193–6

    PubMed  CAS  Google Scholar 

  87. Kienbaum S, Lehmann P, Ruzicka T. Topical calcipotriol in the treatment of intertriginous psoriasis. Br J Dermatol 1996; 135: 647–50

    PubMed  CAS  Google Scholar 

  88. Saurat J-H, Gumowski Sunek D, Rizzoli R. Topical calcipotriol and hypercalcaemia [letter]. Lancet 1991; 337: 1287

    Google Scholar 

  89. Barker JN, Ashton RE, Marks R, et al. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999; 141: 274–8

    PubMed  CAS  Google Scholar 

  90. Veien NK, Bjerke JR, Rossmann-Ringdahl I, et al. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol: a double-blind trial. Br J Dermatol 1997; 137: 581–6

    PubMed  CAS  Google Scholar 

  91. Foster RH, Brogden RN, Benfield P. Tazarotene. Drugs 1998; 55: 705–11

    PubMed  CAS  Google Scholar 

  92. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy and duration of therapeutic effect. J Am Acad Dermatol 1997; 37: 85–92

    PubMed  CAS  Google Scholar 

  93. Lebwohl M. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol 2000; 43: S43–6

    PubMed  CAS  Google Scholar 

  94. Hecker D, Worsley J, Yueh G, et al. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol 1999; 41: 927–30

    PubMed  CAS  Google Scholar 

  95. Krochmal L, Wang JCT, Patel B. Topical corticosteroid compounding: effects on physiochemical stability and skin penetration rate. J Am Acad Dermatol 1989; 21: 979–84

    PubMed  CAS  Google Scholar 

  96. Von Weiss JF, Lever WF. Percutaneous salicylic acid intoxication in psoriasis. Arch Dermatol 1964; 90: 614–9

    Google Scholar 

  97. Schissel DJ, Elston DM. Topical 5-fluorouracil treatment for psoriatic trachyonychia. Cutis 1998; 62: 27–8

    PubMed  CAS  Google Scholar 

  98. Pearlman DL, Youngberg B, Engelhard C. Weekly pulse dosing schedule of fluorouracil: a new topical therapy for psoriasis. J Am Acad Dermatol 1986; 15: 1247–52

    PubMed  CAS  Google Scholar 

  99. Coven TR, Burack LH, Gilleaudeau R, et al. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol 1997; 133: 1514–22

    PubMed  CAS  Google Scholar 

  100. Van Weelden H, De La Faille HB, Young E, et al. A new development in UVB phototherapy of psoriasis. Br J Dermatol 1988; 119: 11–9

    PubMed  Google Scholar 

  101. Green C, Ferguson J, Lakshmipathi T, et al. 311 nm UVB phototherapy: an effective treatment for psoriasis. Br J Dermatol 1988; 119: 691–6

    PubMed  CAS  Google Scholar 

  102. Van Weelden H, Baart de la Faille H, Young E, et al. Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis. Acta Derm Venereol 1990; 70(3): 212–5

    PubMed  Google Scholar 

  103. Iest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989; 120: 665–70

    PubMed  CAS  Google Scholar 

  104. Tanew A, Radakovic-Fijan S, Schemper M, et al. Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: a paired comparison study. Arch Dermatol 1999; 135: 519–24

    PubMed  CAS  Google Scholar 

  105. Cox NH, Jones SK, Downey DJ, et al. Cutaneous and ocular side-effects of oral photochemotherapy: results of an 8-year follow-up study. Br J Dermatol 1987; 116: 145–52

    PubMed  CAS  Google Scholar 

  106. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis: photochemotherapy follow-up study. Cancer 1994; 73: 2759–64

    PubMed  CAS  Google Scholar 

  107. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336: 1041–5

    PubMed  CAS  Google Scholar 

  108. Tanew A, Guggenbichler A, Honigsmann H, et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991; 25: 682–4

    PubMed  CAS  Google Scholar 

  109. Asa Wanonda P, Anderson RR, Chang Y, et al. 308nm excimer laser for the treatment of psoriasis: a dose-response study. Arch Dermatol 2000; 136: 619–24

    CAS  Google Scholar 

  110. Lebwohl M, Ali S. Treatment of psoriasis: Pt 2. systemic therapies. J Am Acad Dermatol 2001; 45: 649–61

    PubMed  CAS  Google Scholar 

  111. Roenigk Jr HH, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 2000; 38: 478–85

    Google Scholar 

  112. Tett SE, Triggs EJ. Use of methotrexate in older patients: a risk-benefit assessment. Drugs Aging 1996; 9: 458–71

    PubMed  CAS  Google Scholar 

  113. Fairris G, Dewhurst A, White JE, et al. Methotrexate dosage in patients aged over 50 with psoriasis. BMJ 1989; 298: 801–2

    PubMed  CAS  Google Scholar 

  114. Tung JP, Maibach HI. The practical use of methotrexate in psoriasis. Drugs 1990; 40: 697–712

    PubMed  CAS  Google Scholar 

  115. Evans W, Christensen M. Drug interactions with methotrexate. J Rheumatol 1985; 12: 15–20

    CAS  Google Scholar 

  116. Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5mg. J Rheumatol 1995; 22: 2072–7

    PubMed  CAS  Google Scholar 

  117. Karim A, Tolbert DS, Hunt TL, et al. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1999; 26(12): 2539–43

    PubMed  CAS  Google Scholar 

  118. Thomas DR, Dover JS, Camp RD. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol 1987; 17: 1055–6

    PubMed  CAS  Google Scholar 

  119. Moy RL, Kinston TP, Lowe NJ. Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol 1985; 121: 1297–301

    PubMed  CAS  Google Scholar 

  120. Ellis CN. Etretinate therapy causes increased lipid levels in patients with psoriasis. Arch Dermatol 1981; 117: 160–80

    Google Scholar 

  121. Wieder JM, Lowe NJ. Systemic retinoids for psoriasis. Dermatol Clin 1995; 13: 891–6

    PubMed  CAS  Google Scholar 

  122. Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998; 39: 464–75

    PubMed  CAS  Google Scholar 

  123. Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporin for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. Br J Dermatol 1999; 141: 283–91

    PubMed  CAS  Google Scholar 

  124. Griffiths CE. Systemic and local administration of cyclosporine in the treatment of psoriasis. J Am Acad Dermatol 1990; 23: 1242–7

    PubMed  CAS  Google Scholar 

  125. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999; 41: 25–8

    Google Scholar 

  126. Laburte C, Grossman R, Abi-Rached J, et al. Efficacy and safety of oral cyclosporine for long term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130: 336–75

    Google Scholar 

  127. Lowe NJ, Wieder JM, Rosenbach A, et al. Long-term low dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996; 35: 710–9

    PubMed  CAS  Google Scholar 

  128. Cather JC, Abramovits W, Menter A. Cyclosporine in dermatology. Dermatol Clin 2001; 19: 119–37

    PubMed  CAS  Google Scholar 

  129. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study: the European FK 506 Multicenter Psoriasis Study Group. Arch Dermatol 1996; 132: 419–23

    Google Scholar 

  130. Grundmann-Kollmann M, Mooser G, Schraeder P, et al. Treatment of chronic plaque stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000; 42: 835–7

    PubMed  CAS  Google Scholar 

  131. Boyd A, Neldner K. Hydroxyurea therapy. J Am Acad Dermatol 1991; 25: 518–24

    PubMed  CAS  Google Scholar 

  132. Zackheim HS, Glogau RG, Fisher DA, et al. 6-thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol 1994; 30: 452–8

    PubMed  CAS  Google Scholar 

  133. Hecker M, Ramos-Caro FA, Ford MJ, et al. Azathioprine: a forgotten alternative for the treatment of severe psoriasis. Int J Dermatol 1992; 31: 873–4

    Google Scholar 

  134. van de Kerkhof PCM. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol 2001; 26: 356–61

    PubMed  Google Scholar 

  135. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454–9

    PubMed  CAS  Google Scholar 

  136. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2001; 46: 1–23

    Google Scholar 

  137. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical severity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829–30

    PubMed  CAS  Google Scholar 

  138. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000; 356: 385–90

    PubMed  CAS  Google Scholar 

  139. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248–55

    PubMed  CAS  Google Scholar 

  140. Papp K, Bissonnette R, Krueger JG, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45: 665–74

    PubMed  CAS  Google Scholar 

  141. Asadullah K, Volk HD, Sterry W. Novel therapies for psoriasis. Trends in Immunol 2002; 23: 47–53

    CAS  Google Scholar 

  142. Bohm M, Voorhees JJ. The role of the ambulatory psoriasis treatment center: a cost effective program for severe psoriasis. J Am Acad Dermatol 1985; 12(4): 740–7

    Google Scholar 

  143. Warin AP. Dermatology day care treatment centers. Clin Exp Dermatol 2001; 26: 351–5

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Affiliations

  1. Department of Dermatology, Wake Forest Medical Center, Medical Center Blvd, Winston Salem, 27157, USA

    Gil Yosipovitch

  2. National Skin Center, Singapore, Singapore

    Mark B. Y. Tang

Authors
  1. Gil Yosipovitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark B. Y. Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yosipovitch, G., Tang, M.B.Y. Practical Management of Psoriasis in the Elderly. Drugs Aging 19, 847–863 (2002). https://doi.org/10.2165/00002512-200219110-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200219110-00003

Keywords

  • Psoriasis
  • Psoriatic Arthritis
  • Topical Corticosteroid
  • Calcipotriol
  • Acitretin